Select a State

Global health R&D delivers for Connecticut

US government investment in global health R&D has delivered

$87.2 million
to Connecticut research institutions
850+ new jobs
for Connecticut

Neglected diseases in Connecticut

Chikungunya cases
55
Dengue cases
49
HIV diagnoses
2,901
Malaria cases
116
Tuberculosis cases
679
West Nile cases
70
Zika cases
58

Connecticut's top USG-funded global health R&D institutions

Yale University
$76.6 million
University of Connecticut (including Health Center and School of Medicine)
$9.9 million
Wesleyan University
$477 thousand
Connecticut Agricultural Experiment Station
$162 thousand

Connecticut industry in global health R&D

Achillion
Location(s):
New Haven
Bristol-Myers Squibb
Location(s):
Wallingford
Charles River Laboratories
Location(s):
Lebanon, North Franklin, Preston, Storrs, Tafville, Voluntown, Willimantic
Gilead
Location(s):
Branford
GSK
Location(s):
Branford
Melinta Therapeutics
Location(s):
New Haven
NanoViricides
Location(s):
Shelton
Pfizer
Location(s):
Groton
Viiv Healthcare
Location(s):
Branford

Connecticut's top areas of global health R&D by USG funding

5.4%
HIV/AIDS
8.5%
Malaria
5.8%
Tuberculosis
3.1%
Diarrheal diseases
20.1%
Salmonella infections
49.3%
Neglected tropical diseases
Dengue
Helminths
Kinetoplastids
7.8%
Other
Non-allocable

Global health R&D at work in Connecticut

Scientists at the University of Connecticut Center of Excellence for Vaccine Research in Storrs are working to develop a vaccine against Zika using a new method devised by the center to speed an early stage of vaccine development. Using this technique, researchers can create a prospective vaccine in a week, rather than months, allowing them to generate multiple variations of a vaccine quickly for further testing. Beyond contributing to the fight against Zika—a mosquito-borne virus linked to devastating birth defects—this technique holds promise to speed vaccine development against many other long-standing and emerging global health threats.

Footnotes